# A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

> **NCT05512390** · PHASE1 · RECRUITING · sponsor: **AbbVie** · enrollment: 154 (estimated)

## Conditions studied

- Diffuse Large B-Cell Lymphoma
- Chronic Lymphocytic Leukemia
- Follicular Lymphoma

## Interventions

- **DRUG:** ABBV-319

## Key facts

- **NCT ID:** NCT05512390
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-26
- **Primary completion:** 2027-02
- **Final completion:** 2027-02
- **Target enrollment:** 154 (ESTIMATED)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05512390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05512390, "A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05512390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*